key: cord-0731308-3lx8u8ou authors: Adams, Elliot; Broce, Mike; Mousa, Albeir title: Proposed Algorithm for Treatment of Pulmonary Embolism in COVID-19 Patients date: 2020-09-04 journal: Ann Vasc Surg DOI: 10.1016/j.avsg.2020.08.088 sha: 03eed00b84e093988c4da032c05d36fc11bdcaf2 doc_id: 731308 cord_uid: 3lx8u8ou There is mounting evidence that COVID-19 patients may possess a hypercoagulable profile that increases their risk for thromboembolic complications, including pulmonary embolism. Pulmonary embolism has been associated with an increase in morbidity, mortality, prolonged ventilation, and extended ICU admissions. Intervention is warranted in some patients who develop acute massive and sub-massive PEs. However, the development of PE in COVID-19 patients is often complicated by such factors as delay of diagnosis, confounding medical conditions, and strict isolation precautions. In addition, depleted cardiopulmonary reserve and prone positioning can make management of pulmonary embolism in these patients especially challenging for the physician. In this paper, we review current understanding of pulmonary embolism in COVD-19 patients, summarize consensus data regarding the treatment of pulmonary embolism, and propose an algorithm to guide the management of COVID-19 patients with pulmonary embolism. There is mounting evidence that COVID-19 patients may possess a hypercoagulable profile that 3 increases their risk for thromboembolic complications, including pulmonary embolism. 4 Pulmonary embolism has been associated with an increase in morbidity, mortality, prolonged 5 ventilation, and extended ICU admissions. Intervention is warranted in some patients who 6 develop acute massive and sub-massive PEs. However, the development of PE in COVID-19 7 patients is often complicated by such factors as delay of diagnosis, confounding medical 8 conditions, and strict isolation precautions. In addition, depleted cardiopulmonary reserve and 9 prone positioning can make management of pulmonary embolism in these patients especially 10 challenging for the physician. In this paper, we review current understanding of pulmonary 11 embolism in COVD-19 patients, summarize consensus data regarding the treatment of 12 pulmonary embolism, and propose an algorithm to guide the management of COVID-19 patients 13 with pulmonary embolism. 14 Since its early diagnosis in December, 2019 in Wuhan, China, the novel enveloped RNA 24 betacoronavirus (COVID-19) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-25 2) has been emerging as global pandemic affecting lives, societies and turning the entire world 26 upside down. The lack of prior immunity to COVID-19 has resulted in exponential increase in 27 numbers of infected patients across the globe and uncertainty regarding management of the 28 complications that may arise in the course of that viral illness. 29 COVID-19 implications on the cardiovascular system include myocardial injury, myocarditis, 30 acute myocardial infarction, heart failure, and dysrhythmias.(1) 31 In addition, COVID-19 infection purportedly causes a hypercoagulable state that results in an 32 increased risk for embolic and thrombotic vascular complications. Amongst these, there is an 33 elevated risk for pulmonary embolism (COVID-PE), with an incidence potentially as high as 20-34 30%.We propose a model for guiding the management of COVID-19 patients with intermediate-35 This article is an attempt to summarize a broad consensus and to propose an algorithm to treat 37 COVID-PE patients. The Inari FlowTriever device is currently the only device the FDA has approved for 102 percutaneous mechanical PE thrombectomy.(10) The FLARE study (11) found a 25% reduction 103 in RV/LV ratio and only 1% incidence of major bleeding in patients with sub-massive PE treated 104 with the FlowTriever device. Of note, the inclusion criteria in this study included hemodynamic 105 The Ekosonic Endovascular System ("EKOS") was the first device approved by the FDA for and unrelenting, requiring the care team to be quick and decisive in their actions. For these 175 reasons, we presented this article as an attempt to both summarize a broad consensus and to 176 Cardiovascular complications in COVID-19 Coagulation disorders in coronavirus infected patients: 218 COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past Microvascular COVID-19 lung vessels 221 obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory 222 distress syndrome working hypothesis Changes in Blood Coagulation in Patients with Severe COVID-19): a Meta-Analysis COVID-19 and its implications for thrombosis and 226 anticoagulation Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Severe Acute Proximal Pulmonary Embolism and 231 COVID-19: A Word of Caution How Fragile Are Clinical Trial Outcomes That 233 Support the CHEST Clinical Practice Guidelines for VTE? Safety and Efficacy of Acute Pulmonary 238 Embolism Treated via Large-Bore Aspiration Mechanical Thrombectomy Using the Inari 239 A Prospective Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary 242 Embolism: The FLARE Study A Prospective Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study A Randomized Trial of the Optimum Duration of 248 Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The 249 COVID-19 pneumonia with hemoptysis: Acute 251 segmental pulmonary emboli associated with novel coronavirus infection Pulmonary Embolism in COVID-19 Patients: 254 Awareness of an Increased Prevalence COVID-19 complicated by Acute Pulmonary 256 Embolism and Right-Sided Heart Failure Uncertainties on the prognostic value of D-260 dimers in COVID-19 patients Age-adjusted D-dimer cut-off levels to rule out venous 262 thromboembolism in COVID-19 patients D-dimer levels on admission to predict in-hospital 264 mortality in patients with Covid-19 COVID-19 in Pregnancy: Consider Thromboembolic Disorders 266 and Thromboprophylaxis Pulmonary embolism in 268 patients with COVID-19: Time to change the paradigm of computed tomography Achieving a Popliteal Venous Access for RRT in Critically Ill 271 COVID-19 Patient in Prone position Thromboembolic risk and anticoagulant 273 therapy in COVID-19 patients: Emerging evidence and call for action High incidence of venous thromboembolic 275 events in anticoagulated severe COVID-19 patients The authors have nothing to declare or disclose.J o u r n a l P r e -p r o o f